Epilepsy

  • Roger J. Porter
Part of the Foundations of Neurology book series (FONY, volume 1)

Abstract

More clinical trials may have been conducted in epilepsy than in any other neurologic disorder. The successful development of new antiepileptic drugs, the hope of finding yet a better medication, and the pecuniary potential of a new, effective, and less toxic drug have caused the literature to be filled with studies of putative antiepileptic compounds. The need is great. If the number of patients worldwide who suffer from epilepsy is near 50 million, one may assume that at least five million of these are poorly controlled and in need of better therapies. For most of these epileptic patients, hope lies in the discovery of new and better medications to control their seizures.

Keywords

NMDA Barbiturate Clonazepam Muscimol Clobazam 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gastaut H (1973). Dictionary of Epilepsy. Geneva: World Health Organization.Google Scholar
  2. 2.
    Porter RJ (1989). Epilepsy: 100 Elementary Principles, 2nd edition. London: Saunders.Google Scholar
  3. 3.
    Taylor J (1931). Selected Writings of John Hughlings Jackson, Vol. I: On Epilepsy and Epileptiform Convulsions. London: Hodder and Stoughton. Reprinted 1958, New York: Basic Books.Google Scholar
  4. 4.
    Gastaut H (1970). Clinical and electroencephalographic classification of epileptic seizures. Epilepsia 11:102–113.PubMedCrossRefGoogle Scholar
  5. 5.
    Commission on Classification and Terminology of the International League Against Epilepsy (1981). Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489–501.CrossRefGoogle Scholar
  6. 6.
    Gastaut H, Broughton R (1972). Epileptic Seizures: Clinical and Electrographic Features, Diagnosis and Treatment. Springfield, IL: Charles C. Thomas.Google Scholar
  7. 7.
    Penry JK, Dreifuss FE (1969). Automatisms associated with the absence of petit mal epilepsy. Arch of Neurol 21:142–149.Google Scholar
  8. 8.
    Penry JK, Porter RJ, Dreifuss FE (1975). Simultaneous recording of absence seizures with videotape and electroencephalography: A study of 374 seizures in 48 patients. Brain 98: 427–440.PubMedCrossRefGoogle Scholar
  9. 9.
    Holmes GL, McKeever M, Adamson M (1987). Absence seizures in children: Clinical and electroencephalographic features. Ann Neurol 21:268–273.PubMedCrossRefGoogle Scholar
  10. 10.
    Porter RJ, Pitlick WH (1989). Antiepileptic drugs. In Katzung BG (ed.), Basic and Clinical Pharmacology, 4th edition. Norwalk, CT: Appelton & Lange, pp. 287–303.Google Scholar
  11. 11.
    Swinyard EA (1982). Introduction. In Woodbury DM, Penry JK, Pippenger CE (eds.), Antiepileptic Drugs, 2nd edition. New York: Raven Press, pp. 1–9.Google Scholar
  12. 12.
    Porter RJ, Nadi NS (1987). Investigations in the pharmacotherapy of the focal epilepsies. In Weiser HG, Speckman EH, Engel J (eds.) The Epileptic Focus. London: John Libbey, pp. 175–191.Google Scholar
  13. 13.
    Porter RJ, Cereghino JJ, Gladding GD, et al. (1984). Antiepileptic drug development program. Cleve Clin Q 51:293–305.PubMedGoogle Scholar
  14. 14.
    Porter RJ (1988). New antiepileptic drugs: Prospects for improved treatment of seizures. In Pedley TA, Meldrum BS (eds.), Recent Advances in Epilepsy, Vol. 4. London: Churchill Livingstone, pp. 161–179.Google Scholar
  15. 15.
    Meldrum BS (1986). Pharmacological approaches to the treatment of epilepsy. In Meldrum BS, Porter RJ (eds.), New Anticonvulsant Drugs. London: John Libbey, pp. 17–30.Google Scholar
  16. 16.
    Porter RJ (1986). Clinical trials relating to epilepsy. In Poeck K, Freund HJ, Ganshirt H (eds.), Proceedings of the 13th World Congress of Neurology. Berlin: Springer-Verlag, pp. 305–312.Google Scholar
  17. 17.
    Mattson RH, Cramer JA, Collins JF, et al. (1985). Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 313:145–151.PubMedCrossRefGoogle Scholar
  18. 18.
    Cereghino JJ, Penry JK (1982). Testing of antiepileptic drugs in humans: Clinical considerations. In Woodbury DM, Penry JK, Pippenger CE (eds.), Antiepileptic Drugs, 2nd edition. New York: Raven Press, pp. 141–157.Google Scholar
  19. 19.
    Sato S, White BG, Penry JK, et al. (1982). Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 32:157–163.PubMedGoogle Scholar
  20. 20.
    Chalmers TC, Celano P, Sacks HS, et al. (1983). Bias in treatment assignment in controlled clinical trials. N Engl J Med 309:1358–1361.PubMedCrossRefGoogle Scholar
  21. 21.
    Kurtzke JF (1986). Neuroepidemiology: Assessment of therapeutic trials. Ann Neurol 19: 311–319.PubMedCrossRefGoogle Scholar
  22. 22.
    Meldrum BS, Porter RJ (eds.) (1986). New Anticonvulsant Drugs. London: John Libbey.Google Scholar
  23. 23.
    Leppik I (in press). Felbamate. Epilepsia.Google Scholar
  24. 24.
    Theodore WH (in press). Felbamate. Epilepsia.Google Scholar
  25. 25.
    Perhach JL, Weliky I, Newton JJ, et al. (1986). Felbamate. In Meldrum BS, Porter RJ (eds.), New Anticonvulsant Drugs. London: John Libbey, pp. 117–123.Google Scholar
  26. 26.
    Vanden Bussche G, Wauquier A, Aston D, et al. (1986). Flunarizine. In Meldrum BS, Porter RJ (eds.), New Anticonvulsant Drugs. London: John Libbey, pp. 125–133.Google Scholar
  27. 27.
    Bartoszyk GD, Meyerson N, Reimann W, et al. (1986). Gabapentin. In Meldrum BS, Porter RJ (eds.), New Anticonvulsant Drugs. London: John Libbey, pp. 147–163.Google Scholar
  28. 28.
    Crawford P, Ghadiali E, Lane R, et al. (1987). Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry 50:682–686.PubMedCrossRefGoogle Scholar
  29. 29.
    Porter RJ (in press). Substances under clinical development. In Dam M, Gram L (eds.), Epileptology: An International Perspective. New York: Raven Press.Google Scholar
  30. 30.
    Miller AA, Sawyer DA, Roth B, et al. (1986). Lamotrigine. In Meldrum BS, Porter RJ (eds.), New Anticonvulsant Drugs. London: John Libbey, pp. 165–177.Google Scholar
  31. 31.
    Roba J, Cavalier R, Cordi A, et al. (1986). Milacemide. In Meldrum BS, Porter RJ (eds.), New Anticonvulsant Drugs. London: John Libbey, pp. 179–190.Google Scholar
  32. 32.
    Norton LC, Laxer KD, Schomer D, et al. (1986). Phase II study to evaluate the efficacy and safety of milacemide (CP 1552S) in the treatment of complex partial seizures in adult patients. Epilepsia 27:648.Google Scholar
  33. 33.
    Troupin AS, Mendius JR, Cheng F, et al. (1986). MK-801. In Meldrum BS, Porter RJ (eds.), New Anticonvulant Drugs. London: John Libbey, pp. 191–201.Google Scholar
  34. 34.
    Wong EHF, Knight AR, Woodruff GN (1988). [3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes. J Neurochem 50:274–281.PubMedCrossRefGoogle Scholar
  35. 35.
    de Graaff JS, Redpath J, Sam AP, et al. (1986). Org 6370. In Meldrum BS, Porter RJ (eds.), New Anticonvulsant Drugs. London: John Libbey, pp. 215–227.Google Scholar
  36. 36.
    Gram L, Philbert A (1986), Oxcarbazepine. In Meldrum BS, Porter RJ (eds.), New Anticonvulsant Drugs. London: John Libbey, pp. 229–235.Google Scholar
  37. 37.
    Morselli PL, Bartholini G, Lloyd KG (1986). Progabide. In Meldrum BS, Porter RJ (eds.), New Anticonvulsant Drugs. London: John Libbey, pp. 237–253.Google Scholar
  38. 38.
    Vincent JC (1986). Stiripentol. In Meldrum BS, Porter RJ (eds.), New Anticonvulsant Drugs. London: John Libbey, pp. 255–263.Google Scholar
  39. 39.
    Schechter PJ (1986). Vigabatrin. In Meldrum BS, Porter RJ (eds.), New Anticonvulsant Drugs. London: John Libbey, pp. 265–275.Google Scholar
  40. 40.
    Taylor CP, McLean JR, Bockbrader HN, et al. (1986). Zonisamide: AD-810, CI-912. In Meldrum BS, Porter RJ (eds.), New Anticonvulsant Drugs. London: John Libbey, pp. 277–294.Google Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Roger J. Porter

There are no affiliations available

Personalised recommendations